Effect of velcade in combination with nanocurcumin in breast cancer 4t1

Mitra Korani,1,* Elham zendeh del,2 Mahmoud reza jafari,3

1. nanotechnology research center, Bu Ali research Institute, Mashhad university of medical sciences ,
2. nanotechnology research center, Bu Ali research Institute, Mashhad university of medical sciences ,
3. Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science



: it is well known that breast cancer has the highest incidence rates of about 30% of all types of cancer in women, and is the second largest leading cause of deaths in females with cancer . bortezomib (ps-341, velcade®) is the first proteosome inhibitor approved by fda with a highly selectivity inhibitor of the 26s proteasome. ps-341 recognise as a therapeutic agent for the treatment to various typs cancers including breast, ovarian, colorectal and multiple myeloma. although ps-341 has been known as the effective therapeutic, the single-agent activity of ps-341 has been limited due to high side effects . curcumin is one of the antitumor agents that derived from the plant curcuma longa l . a few reports exists in curcumin has synergistic effect of bortezomib in cancer cell lines.


In this study, velcade concentrations used 3.4 nm to 0.05 nm and curcumin concentrations used 40 to 1.25 µm . the cytotoxicity of ps-341 , free curcumin(fc) and nanocurcumin(nc) were determined by mtt assay.


: due to the anticancer ability of bortezomib , curcumin and nanocurcumin(nc) we were seen the combined these antitumor agents synergistically effect on b16f0 cell line. this combination treatment synergistically inhibited the growth of 4t1 cells as compared to controls.


These results indicate that curcumin and nanocurcumin potentiates the therapeutic efficacy of bortezomib in breast cancer 4t1 cell line suggesting this combination therapy to be of value in the in vivo study and clinical management of breast cancer.


Bortezomib,curcumin, nanocurcumin, synergistic effect